Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Semnur Pharmaceuticals Q3 2026 Results: Net Loss of $3.63M, Loss Narrows

Semnur Pharmaceuticals reported a net loss of $12.56 million for the nine months ended September 30, 2026, increasing its accumulated deficit to $288.36 million. The company maintains a significant stockholders' deficit of $33.31 million and relies heavily on a related party loan of $24.04 million to fund its operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.6-152.6
EPS (diluted, $ a share)$-0.02$-0.76

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: SMNR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Semnur Pharmaceuticals, Inc.: key numbers

Share price
$0.4700Close, Nov 13
Market cap
$102M
Shares outstanding
217.71MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.